Close
Translational research in MND: our partnership with LifeArc

Translational research in MND: our partnership with LifeArc

Reading Time: 4 minutes Translational Research is the term used to describe studies that are the bridge between fundamental laboratory-based research and the testing of potential therapies (often by pharmaceutical companies) in the clinic. Without the continued journey of research concepts and ideas from all research and development stages from ‘bench to bedside’ it is almost impossible to develop…

Connecting Patient Data and Artificial Intelligence to Advance MND Research

Connecting Patient Data and Artificial Intelligence to Advance MND Research

Reading Time: 5 minutes “The search for new drugs to help MND patients is a long and challenging one, but it is one where we are beginning to see hope for the future emerging on several fronts. New Artificial Intelligence (AI) data analysis techniques and larger, more detailed collections of patient data have been pivotal in these advances.” Dr…

Updates on Tofersen Trials for SOD1-MND

Updates on Tofersen Trials for SOD1-MND

Reading Time: 6 minutes Global biotechnology company Biogen has announced plans to make tofersen, a potential treatment for people whose MND is believed to be driven by mutations in the SOD1 gene, available to more people on an early access programme. Biogen have also revealed that they are conducting a new Phase 3 clinical trial of tofersen in those…

Spotlight on the ‘International’ Symposium experience

Spotlight on the ‘International’ Symposium experience

Reading Time: 4 minutes We recently announced that following the success of our first virtual International Symposium on ALS/MND (the largest medical and scientific conference specific to MND/ALS) last year and the ongoing challenges caused by the global pandemic, the MND Association’s 32nd Symposium in December 2021 will be held online. As we head towards our Symposium this year,…